Ala Wai Pharma

Ala Wai Pharma is a clinical-stage biotechnology company focused on developing next-generation peptide therapeutics for metabolic disorders. The company's lead program, AW-101, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, designed to provide superior weight loss and glycemic control compared to existing dual agonists. Ala Wai Pharma leverages advanced peptide engineering to optimize the pharmacokinetic and pharmacodynamic profiles of its candidates. The company aims to address the global epidemic of obesity and its associated comorbidities through highly potent and well-tolerated treatments. Founded by industry veterans, the company is currently advancing its lead asset through early clinical development.